PMID- 12879129
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20031107
LR  - 20191107
IS  - 0214-0934 (Print)
IS  - 0214-0934 (Linking)
VI  - 13
IP  - 10
DP  - 2000 Dec
TI  - The dendritic cell advantage: New focus for immune-based therapies.
PG  - 581-6
AB  - Dendritic cells (DCs) provide a much earlier and antigen-specific means for 
      manipulating the immune response. The best-studied function of DCs is to convert 
      antigens into immunogens for T cells. The "DC advantage" entails a myriad of 
      functions. DCs are more than antigen-presenting cells; they are accessories or 
      adjuvants or catalysts for triggering and controlling immunity. Another special 
      feature of DCs is their location and movement in the body; DCs are stationed at 
      surfaces where antigens gain access to the body. The events that make up the life 
      history of DCs are now being unraveled in molecular terms. As research on DCs 
      expands, more potential functions and more sites for their manipulation are 
      becoming apparent.
FAU - Steinman, R M
AU  - Steinman RM
AD  - Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New 
      York, New York 10021-6399, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Drug News Perspect
JT  - Drug news & perspectives
JID - 8809164
EDAT- 2003/07/25 05:00
MHDA- 2003/07/25 05:01
CRDT- 2003/07/25 05:00
PHST- 2003/07/25 05:00 [pubmed]
PHST- 2003/07/25 05:01 [medline]
PHST- 2003/07/25 05:00 [entrez]
AID - 207 [pii]
AID - 10.1358/dnp.2000.13.10.858448 [doi]
PST - ppublish
SO  - Drug News Perspect. 2000 Dec;13(10):581-6. doi: 10.1358/dnp.2000.13.10.858448.